EGFR and non-small cell lung carcinoma: In NSCLC, a phase I study showed clinical activity of EGFR-CAR-T cells, with 2 PR and 5 SD among 11 patients (46), and ROR1-directed CAR-T cells showed preliminary positive results in ROR1+ tumors (4 PR among 6 patients) (47).